Ascentage Pharma, a China-based drug maker, has raised $126.4m from a US IPO that will primarily support its two late-stage cancer therapies. Currently, its only commercial product is olverembatinib, approved as a treatment for some chronic myeloid leukaemia patients in China. The IPO funds will also support the development and potential commercial launch of its blood cancer drug, lisaftoclax. Ascentage has been trading on the Hong Kong Stock Exchange since 2019.
Another Healthcare Data Breach Compromised a Million Patients’ Information
The Community Health Center (CHC) in Connecticut has revealed a data breach that has put the personal and health data of over a million patients
